Holen Sie sich die Stockscreener-App
7.34
6.50%
-0.51
Handel nachbörslich:
7.21
-0.13
-1.77%
Schlusskurs vom Vortag:
$7.85
Offen:
$7.5
24-Stunden-Volumen:
1.25M
Relative Volume:
0.76
Marktkapitalisierung:
$485.16M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.5651
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
-12.20%
1M Leistung:
+0.96%
6M Leistung:
-17.71%
1J Leistung:
-78.78%
1-Tages-Spanne:
$7.125
$7.6473
1-Wochen-Bereich:
$7.125
$8.5819
52-Wochen-Spanne:
$5.00
$45.20
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
7.34 | 485.16M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series - ADVFN
Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer - marketscreener.com
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves -1.94%: What You Should Know - Yahoo Finance
Lobbying Update: $60,000 of GINKGO BIOWORKS INC. lobbying was just disclosed - Nasdaq
Ginkgo Bioworks (DNA): Building Life On Demand - Securities.io
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Ginkgo Bioworks secures $29 million ARPA-H contract By Investing.com - Investing.com South Africa
Ginkgo Bioworks secures $29 million ARPA-H contract - Investing.com Australia
Ginkgo Bioworks, Partners Awarded $29 Million Contract to Stabilize Pharmaceutical Supply Chains - MarketScreener
Wall Street Analysts Think Ginkgo Bioworks (DNA) Could Surge 41.59%: Read This Before Placing a Bet - Yahoo Finance
Ginkgo Bioworks awarded $29 million contract by Arpa-H - marketscreener.com
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply ChainsUsing Amber Waves of Grain - Nasdaq
(DNA) Trading Report - news.stocktradersdaily.com
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways - Yahoo Finance
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Is Ginkgo Bioworks Holdings, Inc. (DNA) the Best Gene-Editing Stock to Buy? - Insider Monkey
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Largest borrow rate increases among liquid names - TipRanks
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
(DNA) Technical Pivots with Risk Controls - Stock Traders Daily
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA) - Yahoo Finance
SBI Securities Co. Ltd. Acquires Shares of 2,905 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why - MSN
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consort - GuruFocus.com
Ginkgo Bioworks (DNA) Insider Trading Activity 2025 - MarketBeat
Ginkgo Bioworks CFO sells shares worth $6,102 - Investing.com India
Ginkgo Bioworks CFO sells shares worth $6,102 By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells shares for over $3k - Investing.com
Y Intercept Hong Kong Ltd Purchases New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
(DNA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022DNA - ACCESS Newswire
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire Inc.
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Simply Wall St
Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownHere's What Happened - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Earnings Results - MarketBeat
DNA; SRNG Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Deadline: January 18, 2022 - ACCESS Newswire
Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Ginkgo Bioworks Shrinks Office and Lab Footprint in Boston, Cambridge - Connect CRE
Ginkgo Bioworks: Revenue Struggles Continue - Seeking Alpha
2025 Is Make Or Break For Ginkgo Bioworks (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):